Ovary Cancer
📧 Sign up to get email alerts when something new happens for Ovary Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-07-02Clinical Trial Results: Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health [NA]
Clinical trial results for adapting multiple behavior interventions to improve cancer survivor health; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery [Phase 3]
Phase 3 trial update on using fluorescence for sentinel lymph node identification in cancer surgery; completed study.
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. [Phase 2]
Phase 2 clinical trial update on tisotumab vedotin with continued treatment in patients with various solid tumors, including gynecologic and…
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Clinical trial evaluating whether fallopian tube cells collected by Cytuity can determine the presence of malignancy compared with removed o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of tisotumab vedotin (HuMax®-TF-ADC) in solid tumors completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-02-20Clinical Trial Update: The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. [Phase 4]
Phase 4 clinical trial evaluating whether a PET/CT imaging agent (18F-ALF-NOTA-PRGD2) can predict efficacy and adverse events of apatinib in…